Home | Business News | Browse by Publication | P | PR Newswire

Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Therapy for Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma (NHL).

Publication: PR Newswire
Publication Date: 22-JUN-09 		Format: Online
Delivery: Immediate Online Access

Article Excerpt
SEATTLE, June 22 /PRNewswire-FirstCall/ -- Updated follow-up phase III EXTEND (PIX 301) clinical trial data enhances previously reported superior response rates for pixantrone over comparator including in high risk patient subgroups



Additional Clinical Studies Also Highlighted at Pan Pacific Conference -- Randomized phase III; PIX 302-Pixantrone plus rituximab significantly improves CR rate (35% vs. 11%), ORR (75% vs. 33%) and time to progression (TTP) (13.2 vs. 8.1 months) compared to rituximab alone in relapsed indolent NHL -- Phase II; AZA I06- Pixantrone plus fludarabine, and rituximab (FPD-R regimen) produces high CR/CRu (70%) and ORR (89%) in multiple relapsed indolent NHL

Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that an overview of CTI's pixantrone clinical studies in aggressive and indolent NHL including follow-up data and subgroup analyses of high risk patients from the phase III EXTEND PIX 301 clinical trial of pixantrone (the "PIX 301 EXTEND trial") is being presented at the Pan Pacific Lymphoma conference by Dr. Richard Van der Jagt of the Ottawa General Hospital.

Pixantrone PIX 301 EXTEND Trial Follow-up Data and Subgroup Analyses

Initial follow-up data in the PIX 301 EXTEND trial demonstrated that three additional patients in the pixantrone arm achieved a CR and one additional patient achieved a CRu during the follow-up period of patients that received chemotherapy on the control arm. Including the treatment and follow-up period, pixantrone had a significantly higher complete remission rate compared to the patients who received standard chemotherapy (CR/CRu rate=24% (17 of 70 patients) for pixantrone vs. CR/CRu rate=7% (5 of...

View this article FREE - Now for a Limited Time, try Goliath Business News
Free for 3 Days!



More articles from PR Newswire
U-Haul Customers Give $1 Million to Charity., June 22, 2009
ATX Provides Connected Vehicle Services to Sixt Rental Car Customers i..., June 22, 2009
Microsoft Mobile Advertising Teams With Hyatt Hotels & Resorts to Driv..., June 22, 2009
Finland's Elisa Awards Amdocs a Six-Year Managed Services and Billing ..., June 22, 2009
XM Satellite Radio to Offer $350 Million of Senior Secured Notes Due 2..., June 22, 2009

Looking for additional articles?
Search our database of over 3 million articles.

Looking for more in-depth information on this industry?
Search our complete database of Industry & Market reports by text, subject, publication name or publication date.

About Goliath
Whether you're looking for sales prospects, competitive information, company analysis or best practices in managing your organization, Goliath can help you meet your business needs.

Our extensive business information databases empower business professionals with both the breadth and depth of credible, authoritative information they need to support their business goals. Whether it be strategic planning, sales prospecting, company research or defining management best practices - Goliath is your leading source for accurate information.